

Appendix files

**Impaired telomere integrity and rRNA biogenesis in  
PARN-deficient patients and knock-out models**

Table of content:


Appendix Figure S1.....	page 2
Appendix Figure S2.....	page 3
Appendix Figure S3.....	page 4
Appendix Figure S4.....	page 5
Appendix Figure S5.....	page 6
Appendix Figure S6.....	page 7
Appendix Table S1.....	page 8
Appendix Table S2.....	page 9
Supplementary References.....	page 10

**Appendix Figure S1**




**Appendix Figure S1.** Pictures showing coarse hairs (**a**) and nail dystrophy (**b**) in individual P1.

**Appendix Figure S2**



**Appendix Figure S2.** The active site of human PARN in complex with RNA (purple) (upper panel, pdb 2A1R (Wu et al, 2005)) is compared to the active site of *S. pombe* POP2 (lower panel, pdb 2P51 (Jonstrup et al, 2007)).  $Mg^{++}$ : green balls; water: red balls. Three aspartate (Hs PARN D28, D292, D382; Sp POP2 D50, D171, D240) and one glutamate (Hs PARN E30; Sp POP2 E52) residues play crucial roles for the hydrolytic reaction mechanism of the DEDDh subfamily of nucleases as the four acidic residues, by coordinating two divalent metal ions, ensure both the substrate binding and the interaction with a molecule of water essential for hydrolysis. The  $N\epsilon 2$  atom of the conserved glutamine (Hs PARN Q68; Sp POP2 Q86) makes an H-bond with the oxygen atom of an amino acid of the neighbour  $\beta$ -strand (Hs PARN Y91 OH; Sp POP2 N108 O $\delta$ 1), whereas the  $O\epsilon 1$  atom of the same glutamine residue is H-bonded to the N atom of the  $\alpha$ -helix N-cap (Hs PARN A379; Sp POP2 A237), located between the catalytic histidine (Hs PARN H377; Sp POP2 H235) and the last aspartic acid (Hs PARN D382; Sp POP2 D240). This last H-bond is likely to play a crucial role in the configuration of the active site, and the p.Gln68His mutation is thus predicted to disturb catalytic activity. Figure made using Chimera (Pettersen et al, 2004).

**Appendix Figure S3**



**Appendix Figure S3.** (a) Splicing aberrations in *PARN* transcripts identified in P2's cells. *PARN* cDNA in patient's cells was PCR amplified, cloned and sequenced. The main splicing events and their frequencies are indicated. 32 independent clones were analyzed. (b) Coverage analysis performed by high throughput sequencing of the whole *PARN* gene sequence (promoter, introns, exons) revealed a two-fold reduction of a genomic region encompassing the *PARN* exons 6 and 7 in P2 and her mother. (c) Sanger sequencing of the boundaries of the deleted region in P2.

### Appendix Figure S4

**a**

RNA guide targeting PARN exon2 : CCGACTTCTTCGCCATCGAT

**b**

clone 2-H

Allele#1: del1bp + 1substitution

<pre> 191 ttctcccgagATTTAAAGACTAATCTTCACAAAGTGTACCAAGCCATAGACGGAGC<b>CCGACTTCTTCGCCATCGAT</b>GGCAGTTTCAGgtatccctccct 290 WT 301 TTCTCCCGAGATTTAAAGACTAATCTTCACAAAGTGTACCAAGCCATAGACGGAGC<b>CCGACTTCTTCGCCATCGAT</b>GGCAGTTTCAGgtatccctccct 399 clone 2-H Allele #1 </pre>
---

Allele #2: insertion 1bp


<pre> 191 ttctcccgagATTTAAAGACTAATCTTCACAAAGTGTACCAAGCCATAGACGGAGC<b>CCGACTTCTTCGCCATCG-A</b>GGCAGTTTCAGgtatccctccct 289 WT 301 TTCTCCCGAGATTTAAAGACTAATCTTCACAAAGTGTACCAAGCCATAGACGGAGC<b>CCGACTTCTTCGCCATCG-A</b>GGCAGTTTCAGgtatccctccct 400 clone 2-H Allele #2 </pre>
---

**c**

<pre> 1 atg gag ata atc agg agc aat ttt aag agt aat ctt cac aaa gtg tac cag gcc ata gag 1 M   E   I   I   R   S   N   F   K   S   N   L   H   K   V   Y   Q   A   I   E 61 gag g<b>cc</b> gac ttc ttc g<b>cc</b> atc gat <b>ggg</b> gag ttt tca gga atc agt gat gga cct tca gtc 21 E   A   D   F   F   A   I   D   G   E   F   S   G   I   S   D   G   P   S   V 121 tct gca tta aca aat ggt ttt gac act cca gaa gag agg tat cag aag ott aaa aag cat 41 S   A   L   T   N   G   F   D   T   P   E   B   R   Y   Q   K   L   K   H 181 tcc atg gac ttt ttg cta ttt cag ttt ggc ctt tgc act ttt aag tat gac tac aca gat 61 S   M   D   F   L   L   F   Q   G   L   C   T   F   K   Y   D   Y   T   D 241 tca aag tat ata acg aag tca ttt aac ttc tat gtt ttc ccg aaa ccc ttc aat aga tcc 81 S   K   Y   I   T   K   S   F   N   F   Y   V   F   P   K   P   F   N   R   S </pre>	<b>WT</b>
--	-----------


<pre> 1 atg gag ata atc agg agc aat ttt aag agt aat ctt cac aaa gtg tac cag gcc ata gag 1 M   E   I   I   R   S   N   F   K   S   N   L   H   K   V   Y   Q   A   I   E 61 gag g<b>cc</b> gac ttc ttc g<b>cc</b> agg <b>atg</b> <b>ggg</b> agt ttt cag gaa tca gtg atg gac ctt cag tct 21 E   A   D   F   F   A   R   M   G   S   F   Q   E   S   V   M   D   L   Q   S 121 ctg cat <b>taa</b> caa atg gtt ttg aca ctc cag aag aga ggt atc aga agc tta aaa agc att 41 L   H   *   Q   M   V   L   T   L   Q   K   R   G   I   R   S   L   K   S   I </pre>	<b>Allele #1</b> <small>NM_002582.3:c.83_84del Chr16(ORCh37):g.14723467_14723468del p.Asp28Glyfs*8</small>	<b>HT1080</b>
<pre> 1 atg gag ata atc agg agc aat ttt aag agt aat ctt cac aaa gtg tac cag gcc ata gag 1 M   E   I   I   R   S   N   F   K   S   N   L   H   K   V   Y   Q   A   I   E 61 gag g<b>cc</b> gac ttc ttc g<b>cc</b> atc gga <b>tgg</b> gga gtt ttc agg aat cag tga tgg acc ttc agt 21 E   A   D   F   F   A   I   G   W   G   V   F   R   N   Q   *   W   T   F   S 121 ctc tgc att aac aaa tgg ttt <b>tga</b> cac tcc aga aga gag gta tca gaa gct taa aaa gca 41 L   C   I   N   K   W   F   *   H   S   R   R   E   V   S   E   A   *   K   A </pre>	<b>Allele #2</b> <small>NM_002582.3:c.83_84insG Chr16(ORCh37):g.14723467_14723468insC p.Asp28Glyfs*9</small>	<b>PARN KO</b>
<pre> 1 atg gag ata atc agg agc aat ttt aag agt aat ctt cac aaa gtg tac cag gcc ata gag 1 M   E   I   I   R   S   N   F   K   S   N   L   H   K   V   Y   Q   A   I   E 61 gag g<b>cc</b> gac ttc ttc g<b>cc</b> atc gga <b>tgg</b> gga gtt ttc agg aat cag tga tgg acc ttc agt 21 E   A   D   F   F   A   I   G   W   G   V   F   R   N   Q   *   W   T   F   S 121 ctc tgc att aac aaa tgg ttt <b>tga</b> cac tcc aga aga gag gta tca gaa gct taa aaa gca 41 L   C   I   N   K   W   F   *   H   S   R   R   E   V   S   E   A   *   K   A </pre>	<b>clone 2-H</b>	

**d**



**Appendix Figure S4.** **(a)** Design of the gRNA used to create CRISPR/Cas9 mutations in the *PARN* coding sequence. **(b)** The HT1080<sup>PARNKO</sup> clone 2-H harbors a 1-bp deletion and a substitution resulting in a frameshift on one allele and 1bp –insertion, also resulting in a frameshift, on the other allele. The blue sequence represents the locus targeted by the gRNA. The pink sequence represents the PAM. **(c)** Premature stop codon generated by both mutations are indicated by red boxes. **(d)** Western Blot analysis confirming the PARN loss of function in HT1080<sup>PARNKO</sup> clone 2-H.

Appendix Figure S5



**Appendix Figure S5.** Ribosomal RNA processing in human cells. Three of the four rRNAs forming the backbones of the small and large ribosomal subunits arise from a long primary transcript (47S pre-rRNA), in which 18S, 5.8S and 28S rRNA sequences are flanked by external (5'ETS, 3'ETS) and internal transcribed spacers (ITS1, ITS2). These rRNAs are progressively released owing to endo- and exoribonucleases. Arrows displayed along the rRNA precursor sequences point out the positions of endonucleolytic cleavage sites. The sequential order of these cleavages defines major and minor, alternative pathways, giving rise to abundant precursors (depicted in grey) or rarer pre-rRNA species (depicted in white). When identified, endoribonucleases are labelled in black, and 5'-3' or 3'-5' exoribonucleases in grey. Question marks refer to putative enzymatic activities deduced from 3'RACE data (Montellese et al, 2017; O'Donohue et al, 2010), or to an RNase described in mouse whose human ortholog could fulfill similar functions (Ansel et al, 2008).

## Appendix Figure S6

**a**

RNA guide targeting mPARN Exon4: GCATTCATGGACTTTTGCG

201 CCTGGCTCTCTGCTGCTGATGTTTATTCCCTTTCGAATGGACTTTTGCGATTCATGGACTTTTGCGTTTCAGTTGGCCTTGTGCTTTAACTATGACCAACAC 300 WT  
 201 CCTGGCTCTCTGCTGCTGATGTTTATTCCCTTTCAGCAGTTCATGGACTTTTGCGTTTCAGTTGGCCTTGTGCTTTAACTATGACCAACAC 298 Parn#25+/-

201 CCTGGCTCTCTGCTGCTGATGTTTATTCCCTTTCGAATGGACTTTTGCGATTCATGGACTTTTGCGTTTCAGTTGGCCTTGTGCTTTAACTATGACCAACAC 300 WT  
 201 CCTGGCTCTCTGCTGCTGATGTTTATTCCCTTTCAGCAGTTCATGGACTTTTGCGTTTCAGTTGGCCTTGTGCTTTAACTATGACCAACAC 299 Parn#29+/-

**b**

1 ATG GAG ATA ATC CGG AGC AAT TTT AAG ATT AAT CTT CAC AAA GTG TAC CAG GCC ATA GAG  
 1 M E I I R S N F K I N L H K V Y Q A I E  
 61 GAG GCT GAC TTC TTA GCC ATC GAT GGG GAG TTT TCA GGA ATC AGC AAT GGA CCC TCA GTA  
 21 E A D F F A I D G E F S G I S N G P S V  
 121 ACA GCA TTA ACA AGT GGT TTT GAC ACC CCA GAA GAG AGA TAT CAG AAG CTT AAA AAG TTC  
 41 T A L T S G F D T P E R Y Q K L K X L  
 181 CCA TGG ACT TTT TGC TGT TTC AGT TTG GCC TTT GTG CTT TTA AGT ATG ACC ACA CAG ATT  
 61 P W T F C C F S L A F V L L S M T T Q I  
 241 CCA AGC ATG TAA CGA AGT CAT TTA ACT TCT ATG TTT TCC CCA AGC CTT TCA GTA GGT CCT  
 81 P S M \* R S H L T S M F S P S L S V G P

WT

1 ATG GAG ATA ATC CGG AGC AAT TTT AAG ATT AAT CTT CAC AAA GTG TAC CAG GCC ATA GAG  
 1 M E I I R S N F K I N L H K V Y Q A I E  
 61 GAG GCT GAC TTC TTA GCC ATC GAT GGG GAG TTT TCA GGA ATC AGC AAT GGA CCC TCA GTA  
 21 E A D F F A I D G E F S G I S N G P S V  
 121 ACA GCA TTA ACA AGT GGT TTT GAC ACC CCA GAA GAG AGA TAT CAG AAG CTT AAA AAG TTC  
 41 T A L T S G F D T P E R Y Q K L K X L  
 181 CAA TGG CTT TTT GGT GTT TCA GTT TGG CCT TTG TGC TTT TAA GTA TGA CCA CAC AGA TTC  
 61 H G L F A V S V W F L C F \* V \* P H R R F  
 241 CCA GCA TGT AAC GAA GTC ATT TAA CTT CTA TGT TTT CCC CAA GCC TTT CAG TAG GTC CTC  
 81 Q A C N E V I \* L L C F P Q A F Q \* V L

Parn#25+/-

1 ATG GAG ATA ATC CGG AGC AAT TTT AAG ATT AAT CTT CAC AAA GTG TAC CAG GCC ATA GAG  
 1 M E I I R S N F K I N L H K V Y Q A I E  
 61 GAG GCT GAC TTC TTA GCC ATC GAT GGG GAG TTT TCA GGA ATC AGC AAT GGA CCC TCA GTA  
 21 E A D F F A I D G E F S G I S N G P S V  
 121 ACA GCA TTA ACA AGT GGT TTT GAC ACC CCA GAA GAG AGA TAT CAG AAG CTT AAA AAG TTC  
 41 T A L T S G F D T P E R Y Q K L K X L  
 181 CCA TGG ACT TTT TGC TGT TTC AGT TTG GCC TTT GTG CTT TTA AGT ATG ACC ACA CAG ATT  
 61 P W T F C C F S L A F V L L S M T T Q I  
 241 CCA AGC ATG TAA CGA AGT CAT TTA ACT TCT ATG TTT TCC CCA AGC CTT TCA GTA GGT CCT  
 81 P S M \* R S H L T S M F S P S L S V G P

Parn#29+/-

**Appendix Figure S6. (a)** Design of the gRNA used to create CRISPR/Cas9 mutations in the mouse *Parn* gene. The blue sequence represents the locus targeted by the gRNA. The pink sequence represents the PAM. **(b)** The Parn#25+/- and Parn#29+/- animal cell lines harbor, respectively, a 2-bp and a 1-bp deletion on one allele, resulting in frameshifts and premature stop codons indicated by red boxes.

**Appendix Table S1.** List of predicted off-target loci sequenced and found in Parn#25+/- and Parn#29+/- animals.

gene name	position	number of mismatches	PAM + gRNA sequence	Sanger sequence
			off-target sequence	
Gm17441/Tctel	chr17:45,679,275-45,679,297	3	cct gcactccatggacttttgc	
Abca1	chr4:53,043,874-53,043,896	4	ccc tcattccaageactttatgc	WT
Efcab5	chr11:76,916,908-76,916,930	4	cct cgattccatggactttgtt	WT
Olfr506	chr7:115,755,996-115,756,018	4	cca tcateccatgtacttttttc	WT
Olfr487	chr7:115,355,846-115,355,868	4	cca tcateccatgtacttttttc	WT
Olfr478	chr7:115,175,660-115,175,682	4	cca tcatcccatgtactttttcc	WT
Garnl3	chr2:32,878,191-32,878,213	4	cca ggaattcagggacttttgc	WT

**Appendix Table S2.** Primers used in this study.

Primer name	Sequence	Reference
<b>ACTB-F</b>	TGTACGCCAACACAGTGCTG	Boros et al., 2014
<b>ACTB-R</b>	GCTGGAAGGTGGACAGCGA	Tilman et al, 2009
<b>hTR-F</b>	TTTGTCTAACCTAACTAAGTGAGAAG	Tilman et al, 2009
<b>hTR-R</b>	TTGCTCTAGAATGAACGGTGG	Tilman et al, 2009
<b>POT1-F</b>	TCAGTCTGTTAAACTCATTGCC	Zaffaroni et al, 2005
<b>POT1-R</b>	TGCACCACCTGAAAAATTATATCC	Zaffaroni et al, 2005
<b>TPP1-F</b>	CCCGCAGAGTTCTATCTCCA	Poncet et al, 2008
<b>TPP1-R</b>	GGACAGTGATAGGCCTGCAT	Poncet et al, 2008
<b>TRF2-F</b>	GACCTTCCAGCAGAAGATGC	Escoffier et al, 2005
<b>TRF2-R</b>	GTTGGAGGATTCCGTAGCTG	Escoffier et al, 2005
<b>TRF1-F</b>	CCACATGATGGAGAAAATTAAGAGTTAT	Lin et al, 2006
<b>TRF1-R</b>	TGCCGCTGCCTTCATTAGA	Lin et al, 2006
<b>RAP1-F</b>	CGGGGAACCACAGAATAAGA	Poncet et al, 2008
<b>RAP1-R</b>	CTCAGGTGTGGTGGATCAT	Poncet et al, 2008
<b>TIN2-F</b>	GTCAGAGGCTCCTGTGGATT	Abreu et al, 2010
<b>TIN2-R</b>	CAGTGCTTCTCCAGCTGAC	Abreu et al, 2010
<b>RTEL1-F</b>	TCCCAAAGATTATTACGCC	Tummala et al, 2015
<b>RTEL1-R</b>	TCTGTAGATGGTTACTCTTG	Tummala et al, 2015
<b>DKC1-F</b>	CTGGAGTCATGAGTGAAAG	Tummala et al, 2015
<b>DKC1-R</b>	CTCATCCTTGTGGTTATCATA	Tummala et al, 2015
<b>p53-F</b>	GAGGTTGGCTCTGACTGTACC	Liu et al, 2015
<b>p53-R</b>	TCCGTCCCAGTAGATTACCAC	Liu et al, 2015
<b>p21-F</b>	GCAGACCAGCATGACAGATT	Liu et al, 2013
<b>p21-R</b>	GGATTAGGGCTCCTCTTGG	Liu et al, 2013
<b>Xp-Yp-F</b>	GCAAAGAGTGAAAGAACGAAAGCTT	Porro et al, 2010
<b>Xp-Yp-R</b>	CCCTCTGAAAGTGGACCAATCA	Porro et al, 2010
<b>16p-F</b>	TGTGTTCAACGCTGCAACTG	Diman et al, 2016
<b>16p-R</b>	AGTTAGAACGGTTCACTGTG	Diman et al, 2016
<b>5p-F</b>	GAGTGCATTAGCATACAGGTG	Diman et al, 2016
<b>5p-R</b>	TCCTAATGCACACGTAACAC	Diman et al, 2016
<b>15q-F</b>	CAGCGAGATTCTCCCAAGCTAAG	Porro et al, 2010
<b>15q-R</b>	AACCCTAACCATGAGCAACG	Porro et al, 2010

## Supplementary References

- Abreu E, Aritonovska E, Reichenbach P, Cristofari G, Culp B, Terns RM, Lingner J, Terns MP (2010) TIN2-tethered TPP1 recruits human telomerase to telomeres in vivo. *Mol Cell Biol* 30:2971-82
- Ansel KM, Pastor WA, Rath N, Lapan AD, Glasmacher E, Wolf C, Smith LC, Papadopoulou N, Lamperti ED, Tahiliani M, Ellwart JW, Shi Y, Kremmer E, Rao A, Heissmeyer V (2008) *Nat Struct Mol Biol* 15:523-30
- Boros J, Arnoult N, Stroobant V, Collet JF, Decottignies A (2014) Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1 $\alpha$  at chromatin. *Mol Cell Biol* 34:3662-74
- Diman A, Boros J, Poulain F, Rodriguez J, Purnelle M, Episkopou H, Bertrand L, Francaux M, Deldicque L, Decottignies A (2016) Nuclear respiratory factor 1 and endurance exercise promote human telomere transcription. *Sci Adv* 2:e1600031
- Escoffier E, Rezza A, Roborel de Climens A, Belleville A, Gazzolo L, Gilson E, Duc Dodon M (2005) A balanced transcription between telomerase and the telomeric DNA-binding proteins TRF1, TRF2 and Pot1 in resting, activated, HTLV-1-transformed and Tax-expressing human T lymphocytes. *Retrovirology* 2: 77
- Jonstrup AT, Andersen KR, Van LB, Brodersen DE (2007) The 1.4-Å crystal structure of the S. pombe Pop2p deadenylase subunit unveils the configuration of an active enzyme. *Nucleic Acids Res* 35: 3153-64
- Lin X, Gu J, Lu C, Spitz MR, Wu X (2006) Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. *Clin Cancer Res* 12: 572
- Liu J-L, Zeng G-Z, Liu X-L, Liu Y-Q, Hu Z-G, Liu Y, Tan N-H, Zhou G-B (2013) Small compound bigelovin exerts inhibitory effects and triggers proteolysis of E2F1 in multiple myeloma cells. *Cancer Sci* 104: 1697-704
- Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X (2015) TP53 loss creates therapeutic vulnerability in colorectal cancer. *Nature* 520:697-701
- Montellose C, Montel-Lehry N, Henras AK, Kutay U, Gleizes PE, O'Donohue MF (2017) Poly(A)-specific ribonuclease is a nuclear ribosome biogenesis factor involved in human 18S rRNA maturation. *Nucleic Acids Res* 45: 6822-36
- O'Donohue MF, Choesmel V, Faubladier M, Fichant G, Gleizes PE (2010) Functional dichotomy of ribosomal proteins during the synthesis of mammalian 40S ribosomal subunits. *J Cell Biol* 190:853-66
- Pettersen EF, Goddard TD, Huang CC, Cough GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera—a visualization system for exploratory research and analysis. *J Comput Chem* 25:1605-12
- Poncet D, Belleville A, t'kint de Roodenbeke C, Roborel de Climens A, Ben Simon E, Merle-Beral H, Callet-Bauchu E, Salles G, Sabatier L, Delic J, Gilson E (2008) Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. *Blood* 111: 23888-91
- Porro A, Feuerhahn S, Reichenbach P, Lingner J (2010) Molecular dissection of telomeric repeat-containing RNA biogenesis unveils the presence of distinct and multiple regulatory pathways. *Mol Cell Biol* 30: 4808-17
- Tilman G, Loriot A, Van Beneden A, Arnoult N, Londono-Vallejo JA, De Smet C, Decottignies A (2009) Subtelomeric DNA hypomethylation is not required for telomeric sister chromatid exchanges in ALT cells. *Oncogene* 28: 1682-93

- Tummala H, Walne A, Collopy L, Cardoso S, de la Fuente J, Lawson S, Powell J, Cooper N, Foster A, Mohammed S, Plagnol V, Vulliamy T, Dokal I (2015) Poly(A)-specific ribonuclease deficiency impacts telomere biology and causes dyskeratosis congenita. *J Clin Invest* 125: 2151-60
- Wu M, Reuter M, Lilie H, Liu Y, Wahle E, Song H (2005) Structural insight into poly(A) binding and catalytic mechanism of human PARN. *EMBO J* 24: 4082-93
- Zaffaroni N, Villa R, Pastorino U, Cirincione R, Incarbone M, Alloisio M, Curto M, Pilotti S, Daidone MG (2005) Lack of telomerase activity in lung carcinoids is dependent on human telomerase reverse transcriptase transcription and alternative splicing is associated with long telomeres. *Clin Cancer Res* 11: 2832-9